作者: Iván D Vélez , Katherine Gilchrist , María P Arbelaez , Carlos A Rojas , Juan A Puerta
DOI: 10.1016/J.TRSTMH.2005.04.002
关键词:
摘要: We report the results of a double-blind, randomized, placebo-controlled clinical trial killed whole-cell Leishmania amazonensis candidate vaccine against American cutaneous leishmaniasis (CL) in Colombia. The subjects were 2597 healthy volunteers with negative leishmanin skin test (LST) selected from rural Colombian soldiers who going to patrol endemic areas. They randomized receive either three doses (n=1295) or placebo (n=1302) given at 20-day intervals. An active and passive case detection system was established follow-up for 1 year after vaccination. Safety efficacy determined by comparing local systemic adverse reactions each dose incidence parasitologically confirmed CL. In groups 101 (7.7%) 88 (6.8%) developed CL respectively. shown be safe but offered no protection caused L. panamensis proposed vaccination schedule.